Stemline Therapeutics Inc  

(Public, NASDAQ:STML)   Watch this stock  
Find more results for STML
13.45
0.00 (0.00%)
After Hours: 13.45 0.00 (0.00%)
Jan 17, 4:27PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 13.24 - 13.65
52 week 5.50 - 16.20
Open 13.55
Vol / Avg. 116,100.00/212,334.00
Mkt cap 340.11M
P/E     -
Div/yield     -
EPS -2.57
Shares 25.29M
Beta -0.02
Inst. own 55%
Mar 14, 2018
Q4 2017 Stemline Therapeutics Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jan 10, 2018
Stemline Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
Dec 11, 2017
Stemline Therapeutics Inc ASH Analyst and Investor Meeting
Nov 9, 2017
Q3 2017 Stemline Therapeutics Inc Earnings Release
Oct 31, 2017
Stemline Therapeutics Inc to Discuss Pivotal Phase 2 Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin -5362.77% -3678.21%
Operating margin -5434.44% -3734.14%
EBITD margin - -3726.43%
Return on average assets -73.68% -46.06%
Return on average equity -88.09% -52.53%
Employees 32 -
CDP Score - -

Address

750 Lexington Ave
NEW YORK, NY 10022-1200
United States - Map
+1-646-5022310 (Phone)
+1-646-3890968 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Stemline Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers. SL-401 consists of IL-3 recombinantly fused to a truncated diphtheria toxin payload. SL-701 is an immunotherapy designed to activate the immune system to attack tumors. SL-701 comprises various short synthetic peptides that correspond to epitopes of targets, including IL-13 receptor subunit alpha-2 (IL-13Ra2), ephrin type-A receptor 2 (EphA2) and survivin, present on brain cancer. SL-801 is an oral, small molecule that reversibly inhibits Exportin-1 (XPO1), also known as Chromosome Region Maintenance-1 (CRM-1), a nuclear transport protein.

Officers and directors

Ivan Bergstein M.D. Chairman of the Board, President, Chief Executive Officer
Age: 51
Bio & Compensation  - Reuters
Kenneth Hoberman Chief Operating Officer
Age: 52
Bio & Compensation  - Reuters
David G. Gionco Chief Accounting Officer, Vice President - Finance
Age: 56
Bio & Compensation  - Reuters
Ron Bentsur Independent Director
Age: 51
Bio & Compensation  - Reuters
Eric L. Dobmeier Independent Director
Age: 48
Bio & Compensation  - Reuters
Alan S. Forman Independent Director
Age: 51
Bio & Compensation  - Reuters
Kenneth J. Zuerblis Independent Director
Age: 58
Bio & Compensation  - Reuters